Stephen is a Research Professor in the Department of Surgery and Director of Tissue Engineering at the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. Dr. Badylak is a pioneer in tissue engineering and holds more than 40 US patents, has authored more than 130 scientific publications and six book chapters, and has been a member of several scientific committees. He has either chaired or been a member of the Scientific Advisory Board of several major medical device companies including DePuy Inc. of Warsaw, IN, Cook Biotech of West Lafayette, IN, Genesis Orthopedics of Cambridge, MA , Sentron Medical Ventures of Cincinnati, OH and ACell, Inc. of Jessup, MD. He is a charter member and one of three United States member governors of the Tissue Engineering Society International. He is also a member of the Society for Biomaterials and the Regenerative Medicine and Stem Cell Biology Society. For his contributions to his field, he has been featured in several publications and has been the recipient of multiple awards, including most recently the Sigma Xi Scientific Society 2002 Research Award.
Dr. Israel Nur has over four decades of research and development (R&D) in biological experience, with a strong focus in plasma and serum derived product industry, in both the public and private sectors. He has proven expertise in developing biosurgical combination products. Most recently, Israel Nur was a senior director at Ethicon, leading the Manufacturing Scientific Team. Before that, he was managing the Ethicon Biosurgery R&D research and innovation team. Prior to the acquisition of Omrix biopharmaceuticals Inc. by JNJ, Dr. Nur was VP, R&D and one of the founders of Omrix. He also developed a line of plasma derived products, including the Intravenous immunoglobulin (OmriGam). During the early 2000s, under his leadership and with the collaboration of the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Israel Defense Forces (IDF), the US Army and the Ministry of Defense, Omrix developed and manufactured a line of biodefense and bioterrorism products. Before joining the industry, Dr. Nur was a Visiting Fellow, Laboratory of Biochemical Pharmacology, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, in Bethesda, Maryland. He started his career in NIH as a research fellow in National Institute of Allergy and Infectious Diseases (NIAID) in Fort Dietrich, Frederick MD.
Dr. Nur is an author of 53 publications in peer review journals and an inventor of more than 40 patents. He earned a Doctor of Philosophy in Biochemistry and a Master of Science in Microbiology from The Hebrew University of Jerusalem in Israel.